Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00566839
Other study ID # MED2112025
Secondary ID enfis12022
Status Completed
Phase Phase 2
First received November 30, 2007
Last updated November 30, 2007
Start date December 2002
Est. completion date October 2005

Study information

Verified date October 2007
Source University of Rome Tor Vergata
Contact n/a
Is FDA regulated No
Health authority Italy: Comitato Etico Indipendente Azienda Ospedaliera Universitaria Policlinico Tor vergata
Study type Interventional

Clinical Trial Summary

Lung volume reduction surgery is effective in improving pulmonary function and quality of life in selected patients with severe emphysema although the morbidity of this surgical procedure is still considerable. Morbidity is mainly addressed to general anesthesia-related adverse effects and surgical trauma deriving from lung resection. Having developed an awake nonresectional lung volume reduction surgery technique, which is performed under sole thoracic epidural anesthesia, we have hypothesized that it could offer satisfactory clinical results and reduced morbidity rate when compared with the conventional surgical procedure.


Description:

There is increasing scientific evidence that resectional lung volume reduction (LVR) can induce long lasting clinical improvements in selected patients with upper-lobe predominant emphysema and that clinical benefit and survival are better than those achieved with maximized medical treatment. The most widely employed surgical technique entails unilateral or bilateral staple resection of the most emphysematous lung tissue performed under general anesthesia through open or thoracoscopic approaches.

However, the type of surgical approach did not modify the considerable procedure-related morbidity, which can be mainly addressed to general anesthesia and surgical trauma deriving from resection of emphysematous lung tissue. Indeed, following resectional LVR expected mortality and pulmonary morbidity are 5.5% and 30%, respectively. Time spent for postoperative recovering is often prolonged with about 30% of patients still hospitalized or in rehabilitation facilities at 1 month and 15% still not at home 2 months after the operation. As a result, the cost-effectiveness of LVR continue to be questioned.

In recent years, the concept of nonresectional LVR is being investigated and new bronchoscopic approaches have been developed in an attempt of reducing the typical shortcomings of resectional LVR. Within the framework of the proposed nonsurgical methods which differ somewhat in physiopathologic bases and mechanism of LVR, a common denominator is that, so far, all needed general anesthesia.

We have developed an awake nonresectional LVR surgery technique, which respects the basic concepts of resectional LVR but adds some theoretical advantages and is performed under sole thoracic epidural anesthesia.

Following an initial pilot study to assess feasibility and early results, we want to analyze in a randomized fashion the perioperative morbidity and comprehensive 2-year results of thoracoscopic lung volume reduction surgery performed by the awake nonresectional or nonawake resectional surgical techniques.


Recruitment information / eligibility

Status Completed
Enrollment 60
Est. completion date October 2005
Est. primary completion date
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria:

- Severe smoking-related emphysema with upper-lobe predominance

- Severe disability (MMRC dyspnea grade>=3) despite maximized medical therapy including respiratory rehabilitation

- No clinically significant sputum production, bronchiectasis or asthma postbronchodilator forced expiratory volume in onee second (FEV1)<40% predicted

- Residual volume (RV)>180% predicted at body plethysmography

- Total Lung capacity>120% predicted

- No instable angina or ventricular arrythmia

- Peak systolic pulmonary artery pressure <50 mmHg at echocardiocolordoppler

- Arterial carbon dioxide (PaCO2)<50 mmHg

- Diffusion capacity of carbon monoxide (DLCO)> 20% predicted

- Quit smoking since at least 4 months

- ASA score<=3

- Body mass index >18 <29

- No comorbid condition that would significantly increase operative risk or negatively affect participation in a vigorous respiratory rehabilitation program

- No neoplastic disease with life expectancy < 12 months

- No previous pleurodesis or thoracotomy in the more affected hemithorax

Exclusion Criteria:

- Radiologic evidence of extensive pleural adhesions with pleural scarring and calcifications on site targeted for LVRS

- Patients refusal or noncompliance to thoracic epidural anesthesia and awake surgery

- Patients refusal or noncompliance to general surgery and one-lung ventilation

- Unfavorable anatomy for thoracic epidural anesthesia

- Previous surgery of the cervical or upper thoracic spine

- Compromised coagulation (thromboplastin time<80%, prothrombin time>40 sec, platelet count<100/nL or bleeding disorder

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Procedure:
awake nonresectional LVRS
Thoracoscopic nonresectional lung volume reduction surgery carried out in awake patients under sole epidural anesthesia through plication of most emphysematous target areas of the lung
Nonawake resectional LVRS
Thoracoscopic lung volume reduction surgery carried out under general anesthesia and one-lung ventilation through nonanatomic resection of the most emphysematous target areas of the lung

Locations

Country Name City State
Italy Policlinico Tor Vergata University Rome

Sponsors (1)

Lead Sponsor Collaborator
University of Rome Tor Vergata

Country where clinical trial is conducted

Italy, 

References & Publications (12)

Mineo TC, Ambrogi V, Pompeo E, Bollero P, Mineo D, Nofroni I; Pulmonary Emphysema Research Group. Body weight and nutritional changes after reduction pneumoplasty for severe emphysema: a randomized study. J Thorac Cardiovasc Surg. 2002 Oct;124(4):660-7. — View Citation

Mineo TC, Ambrogi V, Pompeo E, Elia S, Mineo D, Bollero P, Nofroni I. Impact of lung volume reduction surgery versus rehabilitation on quality of life. Eur Respir J. 2004 Feb;23(2):275-80. — View Citation

Mineo TC, Pompeo E, Mineo D, Ambrogi V, Ciarapica D, Polito A. Resting energy expenditure and metabolic changes after lung volume reduction surgery for emphysema. Ann Thorac Surg. 2006 Oct;82(4):1205-11. — View Citation

Mineo TC, Pompeo E, Mineo D, Rogliani P, Leonardis C, Nofroni I. Results of unilateral lung volume reduction surgery in patients with distinct heterogeneity of emphysema between lungs. J Thorac Cardiovasc Surg. 2005 Jan;129(1):73-9. — View Citation

Mineo TC, Pompeo E, Mineo D, Tacconi F, Marino M, Sabato AF. Awake nonresectional lung volume reduction surgery. Ann Surg. 2006 Jan;243(1):131-6. — View Citation

Mineo TC, Pompeo E, Rogliani P, Dauri M, Turani F, Bollero P, Magliocchetti N. Effect of lung volume reduction surgery for severe emphysema on right ventricular function. Am J Respir Crit Care Med. 2002 Feb 15;165(4):489-94. — View Citation

Mineo TC, Pompeo E. Long-term results of tailored lung volume reduction surgery for severe emphysema. Clin Ter. 2007 Mar-Apr;158(2):127-33. — View Citation

Pompeo E, De Dominicis E, Ambrogi V, Mineo D, Elia S, Mineo TC. Quality of life after tailored combined surgery for stage I non-small-cell lung cancer and severe emphysema. Ann Thorac Surg. 2003 Dec;76(6):1821-7. — View Citation

Pompeo E, Marino M, Nofroni I, Matteucci G, Mineo TC. Reduction pneumoplasty versus respiratory rehabilitation in severe emphysema: a randomized study. Pulmonary Emphysema Research Group. Ann Thorac Surg. 2000 Sep;70(3):948-53; discussion 954. — View Citation

Pompeo E, Mineo TC. Two-year improvement in multidimensional body mass index, airflow obstruction, dyspnea, and exercise capacity index after nonresectional lung volume reduction surgery in awake patients. Ann Thorac Surg. 2007 Dec;84(6):1862-9; discussion 1862-9. — View Citation

Pompeo E, Mineo TC; Pulmonary Emphysema Research group. Long-term outcome of staged versus one-stage bilateral thoracoscopic reduction pneumoplasty. Eur J Cardiothorac Surg. 2002 Apr;21(4):627-33; discussion 633. — View Citation

Tacconi F, Pompeo E, Mineo TC. Late-onset occult pneumothorax after lung volume-reduction surgery. Ann Thorac Surg. 2005 Dec;80(6):2008-12. — View Citation

* Note: There are 12 references in allClick here to view all references

Outcome

Type Measure Description Time frame Safety issue
Primary mortality 3 months Yes
Primary Hospital stay 2 months Yes
Primary Forced expiratory volume in one second 24 months No
Primary Residual volume 24 months No
Primary Modified Medical research Council Dyspnea index 24 months No
Secondary Arterial carbon dioxide tension (mmHg) 2 days Yes
Secondary Arterial oxygen to fraction of inspired oxygen ratio (PaO2/FiO2) 2 days Yes
Secondary Anesthesia satisfaction score (graded from 1=unsatisfactory to 4=Excellent) 1 day (24h post-surgery) No
Secondary Six minute walking test distance (m) 24 months No
Secondary Short form 36-item quality of life physical function domain score 24 months No
Secondary Body mass index (Kg/m2) 24 months No
See also
  Status Clinical Trial Phase
Recruiting NCT00995852 - Unilateral Versus Bilateral Endoscopic Lung Volume Reduction A Comparative Case Study Phase 2/Phase 3
Completed NCT01860898 - A Phase I Study of iPS Cell Generation From Patients With COPD N/A
Completed NCT00123422 - Innovation in Pulmonary Rehabilitation N/A
Recruiting NCT02879331 - Clinical Study to Evaluate the Exercise Capacity in Patients With Severe Emphysema Treated With Coils N/A
Completed NCT01507415 - Do the SPPB and 4-metre Gait Speed Predict Hospital Readmission in Patients Hospitalised for Acute Exacerbation if COPD? N/A
Completed NCT01051258 - AeriSeal System for Lung Volume Reduction Phase 1/Phase 2
Completed NCT00680056 - Add-on Effects of Tiotropium Over Formoterol in Exercise Tolerance on Chronic Obstructive Pulmonary Disease Patients Phase 4
Completed NCT01872624 - Safety Study of Bone-marrow Derived Mesenchymal Stromal Cells Associated With Endobronchial Valves in Emphysema N/A
Completed NCT01110252 - Safety Study of Cell Therapy to Treat Chronic Obstructive Pulmonary Disease N/A
Completed NCT00517998 - Israeli Biologic Lung Volume Reduction (BLVR) Phase 1 Emphysema Study Phase 1
Terminated NCT00205920 - Netherlands 10 mL Bronchoscopic Lung Volume Reduction (BLVR) Phase 1/2 Emphysema Study - Initial Formulation Phase 2
Withdrawn NCT01849159 - Clinical Study of the Efficacy and Safety of the Application of Allogeneic Mesenchymal (Stromal) Cells of Bone Marrow, Cultured Under the Hypoxia in the Treatment of Patients With Severe Pulmonary Emphysema Phase 1/Phase 2
Completed NCT01869205 - The Effect and Mechanism of Bronchoscopic Lung Volume Reduction by Endobronchial Valve in Korean Emphysema Patients Phase 3
Terminated NCT01320566 - A Continuation Study of the AeriSeal® System Administered at 3 to 4 Sites During a Single Treatment Session for Lung Volume Reduction in Patients With Advanced Emphysema Phase 2/Phase 3
Completed NCT00683722 - PROCHYMAL™ (Human Adult Stem Cells) for the Treatment of Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) Phase 2
Active, not recruiting NCT04465461 - Video Assisted Thoracic Surgery (VATS) Fissure Completion Prior to Zephyr® Endobronchial Valve Insertion N/A
Completed NCT04012359 - Description of Bullous Emphysema Using Lung Ultrasound and Comparison to the Characteristics of Pneumothorax
Recruiting NCT04918706 - Allogeneic MSC Treatment for Pulmonary Emphysema Phase 2
Terminated NCT01449292 - Study of the AeriSeal System for HyPerInflation Reduction in Emphysema (ASPIRE) Phase 3
Completed NCT00347659 - US 10 mL Biologic Lung Volume Reduction (BLVR) Phase 1 Emphysema Study Phase 1